RxDoctor Payments Data

Adharsh Sahadevan, MD

Psychiatry · Scranton, PANPI 1376703769

Payments from drug & device makers

$4,124in general payments, 2019–2025

Across 231 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Johnson & Johnson$840
  • AbbVie$493
  • Otsuka America Pharmaceutical, Inc.$460
  • Neurocrine Biosciences, Inc.$255
  • Alkermes, Inc.$227
  • plus $488 from 8 others

What the payments were for

  • Food & beverage$4,02898%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,124 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$147,689
Medicare patients
290
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$105,253
Invega SustennaPaliperidone Palmitate14$48,028
TrintellixVortioxetine Hydrobromide16$10,125
Clozapine118$9,740
Chlorpromazine Hcl16$6,384
Divalproex Sodium ErDivalproex Sodium121$5,981
Fluphenazine Hcl28$4,712
Aripiprazole156$3,660
Quetiapine Fumarate238$2,781
Olanzapine154$2,532
Carbamazepine ErCarbamazepine32$2,358
Fluoxetine Hcl152$2,287
Risperidone149$1,882
Lamotrigine143$1,528
Benztropine Mesylate133$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$255$105,25312 claims
Johnson & JohnsonInvega Sustenna$840$48,02814 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$10,12516 claims
Almatica Pharma LLCSertraline Hcl$20$1,14997 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →